NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the following upcoming investment conferences:
-- SIGnificant Investment Options in Healthcare by Susquehanna Financial Group -- March 1, 2007 at 1:30 PM at the Omni Berkshire Place Hotel in New York City; -- Cowen and Company Annual Healthcare Conference -- March 13, 2007 at 8:00 AM at the Marriott Copley Place in Boston.
In addition, Achillion senior scientists will participate in the following panel discussions during the SIGnificant Investment Options in Healthcare conference:
-- John Pottage, M.D., Chief Medical Officer, will participate in a panel discussion at 8:00 AM entitled, "Antibiotic Resistance: Challenges/Opportunities in MRSA, C. difficile, and S. pneumonia"; -- Milind S. Deshpande, Ph.D., Achillion's Chief Scientific Officer, will participate in a panel discussion at 10:00 AM entitled, "Hepatitis C Virus: What to Target -- Proteases, Polymerases or Replicases?" About Achillion
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000. ACHN-G
Contact: Media: Mary Kay Fenton Kari Watson Achillion Pharmaceuticals, Inc. MacDougall Biomedical Communications Tel. (203) 624-7000 Tel. (508) 647-0209 firstname.lastname@example.org email@example.com
Source: Achillion Pharmaceuticals, Inc.